Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

770
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
770
Glucose Transporters01:27

Glucose Transporters

27.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.7K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

747
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
747
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

650
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
650
Urine Studies II: Urine Culture and Sensitivity Test01:26

Urine Studies II: Urine Culture and Sensitivity Test

1.5K
A urine culture and sensitivity test is a diagnostic procedure used to identify urinary tract bacterial infections and determine the most effective antibiotics for treatment. This test is generally preferred when a patient shows manifestations of a urinary tract infection, such as frequent or painful urination, cloudy or foul-smelling urine, or lower abdominal pain.Purpose of the TestThe primary goals of a urine culture and sensitivity test are to:Determine the specific bacteria causing the...
1.5K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

190
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opioid agonist treatment and risk of mortality in French primary care: a nationwide, retrospective cohort study.

The Lancet. Public health·2026
Same author

Reply to "A Comment about AI Methods that May Help Advance Pharmacovigilance".

Clinical pharmacology and therapeutics·2026
Same author

Drug prescription before and after dialysis initiation in older patients: a nationwide study.

BMC geriatrics·2026
Same author

Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study.

Acta oncologica (Stockholm, Sweden)·2026
Same author

PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies.

Scientific reports·2026
Same author

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle-Aquitaine.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: Feb 24, 2026

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

8.9K

SGLT-2 Inhibitors Use in Hospitalized Patients in France: A Cross-Sectional Study.

Maxime Demourgues1, Julien Bezin1, Romain Griffier2

  • 1Inserm U1219, Bordeaux Population Health Research Center, Team AHeaD, Department of Medical Pharmacology, CHU de Bordeaux, University of Bordeaux, Bordeaux, France.

Fundamental & Clinical Pharmacology
|February 23, 2026
PubMed
Summary

Sodium glucose co-transporter type 2 inhibitors (SGLT2i) are now mainly used for heart failure (HF), with their kidney benefits underestimated. Prescription compliance with guidelines is generally satisfactory, though some suboptimal use cases exist.

Keywords:
chronic kidney diseasediabetes mellitusdrug utilizationsheart failurepharmacoepidemiologysodium‐glucose transporter 2 inhibitorstype 2

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

15.2K

Related Experiment Videos

Last Updated: Feb 24, 2026

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

8.9K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

15.2K

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Sodium glucose co-transporter type 2 inhibitors (SGLT2i) were initially developed for type 2 diabetes (T2DM).
  • Indications expanded to heart failure (HF) and chronic kidney disease (CKD), increasing real-world use.
  • Patient profiles and treatment patterns diversified following expanded indications.

Purpose of the Study:

  • To describe in-hospital SGLT2i user profiles.
  • To evaluate guideline compliance for SGLT2i prescriptions.

Main Methods:

  • A descriptive cross-sectional study was conducted.
  • Data from 250 hospital stays of SGLT2i users were analyzed.
  • User profiles and co-prescriptions were examined for guideline adherence.

Main Results:

  • Most SGLT2i users were aged 60-79 (59.6%) and male (75.2%).
  • Heart failure (HF) was the primary indication (87.2%), followed by T2DM (45.2%) and CKD (21.2%).
  • Prescriptions were guideline-compliant for 76.4% of patients; suboptimal use often involved omitting other recommended medications.

Conclusions:

  • SGLT2i are predominantly prescribed for HF in current clinical practice.
  • The therapeutic potential of SGLT2i for CKD may be underutilized.
  • Overall adherence to SGLT2i prescribing guidelines is satisfactory.